CODX is trading 12.2% up at $9.57 as shares attempt to stabilize following a period of extreme volatility and a sharp pullback from recent highs.
- The move appears driven by traders repositioning and short-covering after the stock previously spiked over 600% on Ebola-related speculation.
- There are no new company-specific developments or fundamental news items to support the current price action.
- Market attention remains focused on Co-Diagnostics’ small revenue base as the recent speculative hype cools.